scholarly journals In Silico Assessment of Efficacy and Safety of IKur Inhibitors in Chronic Atrial Fibrillation: Role of Kinetics and State-Dependence of Drug Binding

2017 ◽  
Vol 8 ◽  
Author(s):  
Nicholas Ellinwood ◽  
Dobromir Dobrev ◽  
Stefano Morotti ◽  
Eleonora Grandi
Keyword(s):  
Atrial Fibrillation ◽  
In Silico ◽  
State Dependence ◽  
Chronic Atrial Fibrillation ◽  
Drug Binding ◽  
Efficacy And Safety

Computer simulation of the role of fibre orientation in cardioversion of chronic atrial fibrillation

2013 ◽  
Vol 46 (4) ◽  
pp. e6-e7
Author(s):  
S.R. Kharche ◽  
T. Stary ◽  
I.V. Biktasheva ◽  
H. Zhang ◽  
V.N. Biktashev
Keyword(s):  
Atrial Fibrillation ◽  
Computer Simulation ◽  
Fibre Orientation ◽  
Chronic Atrial Fibrillation

scholarly journals Efficacy and safety of lenvatinib in an elderly patient with metastatic papillary thyroid carcinoma and cardiological comorbidity: a case report

2019 ◽  
Vol 15 (24s) ◽  
pp. 27-33 ◽  
Author(s):  
Agnese Latorre ◽  
Agnese Maria Fioretti ◽  
Francesco Giotta ◽  
Vito Lorusso
Keyword(s):  
Atrial Fibrillation ◽  
Thyroid Carcinoma ◽  
Progression Free Survival ◽  
Chronic Atrial Fibrillation ◽  
Differentiated Thyroid Carcinoma ◽  
Phase Iii ◽  
Efficacy And Safety ◽  
Papillary Thyroid ◽  
Free Survival ◽  
Select Trial

Lenvatinib significantly prolonged progression-free survival versus placebo in patients with radio-iodine refractory differentiated thyroid carcinoma. However, the primary adverse effects of any grade that occurred in >40% of patients in the lenvatinib group of the Phase III SELECT trial was hypertension (67.8%). Therefore, this drug should be used with caution in patients with cardiological morbidity. Here, we describe the case of a 73-year-old man with hypertension, obesity and chronic atrial fibrillation, who received lenvatinib for 6 months in the absence of cardiological symptoms.

Role of atrial pressure in the success of electrical cardioversion of chronic atrial fibrillation

2000 ◽  
Vol 86 (2) ◽  
pp. 223-226 ◽  
Author(s):  
Ömer Akyürek ◽  
Fatih Sinan Ertaş ◽  
Erdem Diker ◽  
Remzi Karaoǧuz ◽  
Muharrem Güldal ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Chronic Atrial Fibrillation ◽  
Electrical Cardioversion ◽  
Atrial Pressure

Amiodarone for the Maintenance of Sinus Rhythm in Patients with Atrial Fibrillation

1995 ◽  
Vol 29 (6) ◽  
pp. 596-602 ◽  
Author(s):  
Patricia A Howard
Keyword(s):  
Atrial Fibrillation ◽  
Sinus Rhythm ◽  
Randomized Trials ◽  
Normal Sinus Rhythm ◽  
Efficacy And Safety ◽  
Long Term Effects ◽  
Normal Sinus ◽  
Review Articles

Objective: To discuss the role of amiodarone for the maintenance of normal sinus rhythm in patients with atrial fibrillation (AF) and review the clinical trial data evaluating the efficacy and safety of amiodarone in patients with AF. Data Sources: A MEDLINE search was used to identify pertinent literature. Additional references were identified from the articles obtained in the search. Key search terms were atrial fibrillation, amiodarone, and sinus rhythm. Study Selection: All studies available at the time the article was prepared evaluating the efficacy and safety of amiodarone in AF were included. In addition, review articles discussing the role of amiodarone in AF were selected. Data Extraction: NO large, prospective, randomized trials have been performed. Data from 8 nonrandomized and 2 randomized trials are reported. Information derived from review articles is discussed. Data Synthesis: In patients with AF, maintenance of normal sinus rhythm is desirable to eliminate symptoms, improve functional capacity, and reduce the risk of thromboembolic complications. Class IA agents traditionally have been used; however, concerns about long-term effects on mortality have focused attention on other agents such as amiodarone. A number of nonrandomized, uncontrolled trials have found amiodarone to be effective for maintaining normal sinus rhythm in patients with AF that is refractory to conventional agents. Two randomized, nonblind trials have found amiodarone's efficacy to be equal to or superior to that of class IA drugs. The findings of these trials must be weighed, however, against the significant potential for toxicity and drug interactions associated with amiodarone. Cardiovascular toxicities, including proarrhythmic effects, appear to be relatively rare. In contrast, noncardiovascular effects are common and potentially serious. Conclusions: Although the preliminary data using amiodarone in AF are encouraging, many questions remain unanswered. Prospective, randomized trials are needed to evaluate the long-term efficacy and safety of amiodarone in patients with AF. Studies also are needed to determine the optimal dosing regimen. Until these data are available, each patient must be evaluated individually, taking into account the relative benefits and risks of therapy. Amiodarone may be particularly useful in patients with significant risks for proarrhythmia and those whose AF is refractory to traditional therapy.

Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation

1991 ◽  
Vol 68 (11) ◽  
pp. 1227-1230 ◽  
Author(s):  
Steven Singh ◽  
Ravinder K. Saini ◽  
John DiMarco ◽  
Jeffrey Kluger ◽  
Robert Gold ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Chronic Atrial Fibrillation ◽  
Efficacy And Safety
Sign in / Sign up

Export Citation Format

Share Document